Table 4.
Summary of the most relevant clinical trials with deacetylase inhibitors in MM
| Drugs | Phase | n | Previous lines | ORR (≥ PR) | CBR (≥ MR) | Response in refractory patients** | Reference | |
|---|---|---|---|---|---|---|---|---|
| ORR (≥ PR) | CBR (≥ MR) | |||||||
| Monotherapy | ||||||||
| Vorinostat | 1 | 13 | 0% | 10% | - | - | Richardson Leuk Lymph 2008116 | |
| Panobinostat | 2 | 38 | 5 | 3% | 5% | - | - | Wolf Leuk Lymph 2012117 |
| Romidepsin | 2 | 13 | 3(2–4) | 0% | 0% | - | - | Niesvizky Cancer 2011115 |
| Givinostat +/− Dex | 2 | 19 | 3(1–8) | 0% | 0% | - | - | Galli Ann Hematol 2010114 |
| Rocilinostat | 1/2 | 13 | 88% ≥ 3 | 0% | 0% | - | - | Raje ASH 2012126 |
| + Bortezomib +/− Dexamethasone | ||||||||
| Vorinostat + Bort +/− Dex | 1 | 23 | 7(3–13) | 43% | 90% | 38% | 88% | Badros Clin Cancer Res 2009118 |
| Vorinostat + Bort +/− Dex | 1 | 34 | 4(1–14) | 27% | 32% | 14% | 14% | Weber Clin Lymph-M-L 2012121 |
| Vorinostat + Bortezomib* | 3 | 317 | 2 (1–3) | 56% | 71% | - | - | Dimopoulos ASH 2011123 |
| Panobinostat + Bort + Dex | 1b | 62 | 2 (1–10) | 68% | 82% | 43% | 71% | San Miguel IMW 2011120 |
| Romidepsin + Bort + Dex | 1/2 | 25 | 2(1–3) | 60% | 72% | - | - | Harrison Blood 2011119 |
| Quisinostat + Bort+Dex | 1b | 18 | 2 (1–3) | 88% | - | - | - | Leleu ASCO 2013122 |
| Vorinostat + Bortezomib$* | 2 | 143 Bort- refractory | 4 (2–17) | 18% | 33% | 18% | 33% | Siegel ASH 2011124 |
| Panobinostat + Bort + Dex$ | 2 | 55 Bort- refractory | 4(2–11) | 35% | 53% | 35% | 53% | Richardson ASH 2012125 |
| + Lenalidomide + Dexamethasone | ||||||||
| Vorinostat + Len + Dex | 1 | 31 | 4 (1–10) | 53% | 70% | 20% | 30% | Richardson ASH 2010191 |
| Vorinostat + Len + Dex$$ | 2 | 29 LD- refractory | 4 (2–13) | 24% | 51% | 24% | 51% | Richter ASH 2011192 |
| Panobinostat + Len + Dex | 1b | 46 | 2 (1–8) | 57% | - | - | - | Mateos ASCO 2010193 |
| Other combinations | ||||||||
| Vorinostat + PLD + Bort | 1 | 32 | 2 (1–9) | 65% | 74% | 45% in Bort-refractory | 64% in Bort- refractory | Voorhees ASH 2011194 |
| Vorinostat +Len + Bort + Dex in RR | 2 | 9 RVD- refractory | 5 (2–10) | 44% | 89% | 44% | 89% | Siegel IMW 2011195 |
| Vorinostat +Len + Bort + Dex in ND | 1 | 30 new diagnosis | 0 | 100% | 100% | - | - | Kaufman ASH 2012196 |
| Panobinostat + Melphalan | 1/2 | 25 | 4 (-17) | 16% | 60% | - | - | Berenson IMW 2011197 |
| Panobinostat + MPT | 1/2 | 24 | 21% ≥2 | 50% | - | - | - | Offidani IMW 2011198 |
| Panobinostat + Carfilzomib | 1/1b | 17 | 5 (2–15) | 35% | 41% | - | - | Shah ASH 201235 |
| Panobinostat + Carfilzomib | 1/2 | 10 | 3 (1–7) | 60% | 70% | - | - | Berdeja ASH 201234 |
*
Data obtained from the presentation at the ASH 2011 meeting
**
Indicates the response in patients previously refractory to the drugs administered in combination with the DAC inhibitors (bortezomib or lenalidomide in their respective combinations)
$
Bortezomib-refractory patients
$$
Lenalidomide- and dexamethasone-refractory patients